Gastrointestinal effects of nonsteroidal anti-inflammatory drugs

Fundamental and Clinical Pharmacology

Volumn 17, Issue 3, 2003, Pages 301-313

  Whittle, Brendan J R ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

COX 2 inhibitors; Intestinal bacteria; Microcirculation; Mucosal barrier; NSAIDs; Prostanoids

Indexed keywords

3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; ACETYLSALICYLIC ACID; BUFFER; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LICOFELONE; LIPOXYGENASE INHIBITOR; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN RADICAL; PEROXYNITRITE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; PROTECTIVE AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SALICYLIC ACID; STOMACH SECRETION INHIBITOR; UNINDEXED DRUG;

BACTERIAL TRANSLOCATION; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG MIXTURE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; EPITHELIUM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATION; INHIBITION KINETICS; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; LEUKOCYTE; LIPOGENESIS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH BLOOD FLOW; STOMACH DISEASE; STOMACH INJURY; STOMACH MUCOSA; STOMACH PROTECTION; THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; ISOENZYMES; MEMBRANE PROTEINS; NITRIC OXIDE DONORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 0038095583     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00135.x     Document Type: Review

References (105)

1. Fries J.F., Miller S.R., Spitz P.W., Williams C.A., Hubert H.B., Bloch D.A. Toward an epidemiology of gastropathy associated with non-steroidal anti-inflammatory drug use. Gastroenterology (1989) 96 647-655.
2. Langman M.J., Weil J., Wainwright P. et al. Risks of bleeding peptic ulcer associated with individual nonsteriodal antiinflammatory drugs. Lancet (1994) 343 1075-1078.
3. Whittle B.J.R. Unwanted effects of aspirin and related agents in the gastrointestinal tract. in: Vane J.R., Botting R.M. (Eds.). Aspirin and other salicylates. Chapman and Hall, London, 1992, pp. 465-509.
4. Whittle B.J.R. Pharmacological approach to the prevention of non-steroidal anti-inflammatory drug-induced gastropathy. Ital. J. Gastroenterol. Hepatol. (1999) 31 (Suppl. 1) S43-47.
5. Hawkey C.J. COX-2 inhibitors. Lancet (1999) 353 307-314.
6. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. A diclofenac derivative without ulcerogenic properties. Eur. J. Pharmacol. (1994) 257 249-255.
7. Davenport H.W. Gastric mucosal injury by fatty and acetylsalicylic acids. Gastroenterology (1964) 46 245-253.
8. Pihan G., Rogers C., Szabo S. Vascular injury in acute gastric mucosal damage. Mediatory role of leukotrienes. Dig. Dis. Sci. (1988) 33 625-632.
9. Boughton-Smith N.K., Whittle B.J.R. The role of leukotrienes in the pathogenesis of gastric ulceration. Pharmacol. Res. Commun. (1998) 20 919-934.
10. Lichtenberger L.M., Wang Z.-M., Romero J.J. et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat. Med. (1995) 1 154-158.
11. Himal H.S., Greenberg L., Boutros M.I.R., Waldon-Edward D., Effect of aspirin on ionic movement and acid hydrolase activity of explants of canine antral and duodenal mucosae. Gastroenterology (1975) 69 439-447.
12. Skidmore I.F., Whitehouse M.W. Concerning the regulation of some diverse biochemical reactions underlying the inflammatory response by salicylic acid, phenylbutazone and other acidic antirheumatic drugs. J. Pharm. Pharmacol. (1966) 18 558-560.
13. Anderson S., Grossman M.I. Profile of pH, pressure and potential difference at gastroduodenal junction in man. Gastroenterology (1965) 49 364-371.
14. Glarborg-Jorgensen T., Weis-Fogh U.S., Neilsen H.H., Olsen H.P. Salicylate- and aspirin-induced uncoupling of oxidative phosphorylation in mitochondria isolated from the mucosal membrane of the stomach. Scand. J. Clin. Lab. Invest. (1976) 36 649-653.
15. Somasundaram S., Hayllar H., Rafi S., Wrigglesworth J.M., Macpherson A.J., Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand. J. Gastroenterol. (1995) 30 289-299.
16. Rainsford K.D., Whitehouse M.W. Anti-inflammatory anti-pyretic salicylic acid esters, with low gastric ulcerogenic activity. Agents Actions (1980) 10 451-456.
17. Fiorucci S., Antonelli E., Santucci L. et al. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology (1999) 116 1089-1106.
18. Whittle B.J.R., Vane J.R. Prostanoids as regulators of gastrointestinal function. in: Johnson L.R. (Ed.). Physiology of the gastrointestinal tract. 2nd edn. Raven Press, New York. 1987. pp. 143-180.
19. Robert A., Nezamis J.E., Lancaster C., Hanchar A.J. Cytoprotection by prostaglandins in rats - prevention of gastric necrosis produced by alcohol. HCl, NaOH, hypertonic NaCl and thermal injury. Gastroenterology (1979) 77 433-443.
20. Hawkey C.J., Whittle B.J.R. Prostaglandins in the management of gastroduodenal ulceration. in: Vane J.R., O'Grady J. (Eds.). Therapeutic applications of prostaglandins. Edward Arnold. London, 1993. pp. 122-140.
21. Whittle B.J.R. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br. J. Pharmacol. (1993) 110 3-17.
22. Granger D.N., Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J. Leukoc. Biol. (1994) 55 662-675.
23. Whittle B.J.R. Nitric oxide in gastrointestinal physiology and Pathology, in: Johnson. L.R. (Ed.). Physiology of the gastrointestinal tract, 3rd edn. Raven Press, New York, 1994. pp. 267-294.
24. Barrachino, M.D., Calatayud S., Canet A., Esplugues J.V. Transdermal nitroglycerin prevents nonsteriodal anti-inflammatory drug gastropathy. Eur. J. Pharmacol. (1995) 281 R3-4.
25. Lanas A., Bajador E., Serrano P. et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. (2000) 343 834-839.
26. Cicala C., Ianaro A., Fiorucci S. et al. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br. J. Pharmacol. (2000) 130 1399-1405.
27. Armour K.J., van't Hof R.J., Armour K.E., Torbergsen A.C., Del Soldato P., Ralston S.H. Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). Arthritis Rheum. (2001) 44 2185-2192.
28. Keeble J.E., Moore P.K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal antiinflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. (2002) 137 295-310.
29. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature (London) New. Biol. (1971) 231 232-235.
30. Main I.H.M., Whittle B.J.R. Investigation of the vasodilator and antisecretory role of prostaglandins in the rat gastric mucosa by use of non-steroidal anti-inflammatory drugs. Br. J. Pharmacol. (1975) 53 217-224.
31. Gerkens J.F., Shand D.G., Flexner C., Nies A.S., Oates J., Data J.L. Effect of indomethacin and aspirin on gastric blood flow and acid secretion. J. Pharmacol. Exp. ther. (1977) 203 646-652.
32. Kauffman G.L., Aures D., Grossman M.I. Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in dogs. G131-134. Am. J. Physiol. (1980) 238
33. Wallace J.L., McKnight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology (2000) 119 705-714.
34. Wallace J.L., Keenan C.M., Granger D.N. Gastric ulceration induced by non-steroidal anti-inflammatory drugs is a neutrophil-dependent process. Am. J. Physiol. (1990) 259 G462-467.
35. Wallace J.L., McKnight W., Miyasaka M. et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am. J. Physiol. (1993) 265 G993-998
36. Wallace J.L. Non-steroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology (1997) 112 1000-1016.
37. Santucci L., Fiorucci S., Di Matteo F.M. Role of tumour necrosis factor alfa release and leucocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology (1995) 108 393-401.
38. Vaananen P.M., Meddings J.B., Wallace J.L. Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am. J. Physiol. (1991) 261 G470-475.
39. Takeuchi K., Ueshima K., Hironaka Y., Fujioka Y., Matsumoto J., Okabe S. Oxygen free radicals and lipid peroxidation in the pathogenesis of gastric mucosal lesions induced by indomethacin in rats. Relation to gastric hypermotility. Digestion (1991) 49 175-184.
40. VanKolfscholten A.A., Hagelen F., Noordwijk V. Butyl hydroxy toluene antagonizes the gastric toxicity but not the pharmacological activity of acetylsalicylic acid in rats. Naunyn Schmiedeberg's Arch. Pharmacol. (1984) 327 283-285.
41. Pihan G., Regillo C., Szabo S. Free radicals and lipid peroxidation in ethanol- or aspirin-induced gastric mucosal injury. Dig. Dis. Sci. (1987) 32 1395-1401.
42. Kitahora T., Guth P.H. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. Gastroenterology (1987) 93 810-817.
43. Asako H., Kubes P., Wallace J.L., Wolf R.E., Granger D.N. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology (1992) 103 146-152.
44. Whittle B.J.R., Higgs G.A., Eakins K.E., Moncada S., Vane J.R. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (London) (1980) 284 271-273.
45. Palmer R.H., Bias P., Buchner A., Elsaesser R. Licofelone (ML3000) an inhibitor of COX-1, COX-2 and 5-LO, is associated with less gastric damage than naproxen and is similar to placebo in man. Gastroenterology(2002) 122 A-54.
46. Sarosiek J., Mitzuta K., Solminary A., Solminary B.L. Effect of acetylsalicylic acid on gastric mucin viscosity, permeability to hydrogen ion, and susceptibility to pepsin. Biochem. Pharmacol. (1986) 35 4291-4295.
47. 2 output in human subjects. Ann. Int. Med. (1987) 106 368-371.
48. Prichard P.J., Kitchingman G.K., Walt R.P., Daneshmend T.K., Hawkey C.J. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. BMJ (1989) 298 493-496.
49. Lu Y.F., Mizutani M., Neya T., Nakayama S. modifies contractile activity in rat small intestines. Scand. J. Gastroenterol. (1995) 30 445-450.
50. Xu X.M., Sansores-Garcia L., Chen X.M., Matijevic-Aleksic N., Du M., Wu K.K. Suppression of inducible cyclo-oxygenase 2 gene transcription by aspirin and sodium salicylate. Proc. Natl. Acad. Sci. USA (1999) 96 5292-5297.
51. Fu J-Y., Masferrer J.L., Seibert K., Raz A., Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. (1990) 265 16737-16740.
52. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA (1991) 88 2692-2696.
53. O'Banion M.K., Sadowski H.B., Winn V., Young D.A. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol. Chem. (1991) 266 23261-23267.
54. Mitchell J.A., Warner T.D. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. (1999) 128 1121-1132.
55. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl J. Med. (2001) 345 433-442.
56. Masferrer J.L., Zweifel B.S., Manning P.T. et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA (1994) 91 3228-3232.
57. Chan C.C., Boyce S., Brideau C. et al.Rofecoxib [Vioxx. MK-0966; 4-(-4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharm. Exp. ther. (1999) 290 551-560.
58. Warner T., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA (1999) 96 7563-7568.
59. Kishimoto Y., Wada K., Nakamoto K., Kawasaki H., Hasegawa J. Levels of cyclo-oxygenase-1 and -2 mRNA expression at various stages of acute gastric injury induced by ischemia-reperfusion in rats. Arch. Biochem. Biophys. (1998) 352 153-157.
60. Maricic N., Ehrlich K., Gretzer B., Schuliogi R., Respondek M., Peskar B.M. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br. J. Pharmacol. (1999) 128 1659-1666.
61. Schmassmann A., Peskar B.M., Stettler C. et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br. J. Pharmacol. (1998) 123 795-804.
62. Jones M.K., Wang H., Peskar B.M., Levin E.M., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med.,(1999) 5 1418-1423.
63. Halter F., Tarnawski A.S., Schmassmann A., Peskar B.M. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut (2001) 49 443-453.
64. Langenbach R., Morham S.G., Tiano H.F. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell (1995) 83 483-492.
65. Whittle B.J.R., Lopez-Belmonte J., Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br. J. Pharmacol. (1990) 99 607-611.
66. Robert A. An intestinal disease produced experimentally by a prostaglandin deficiency. Gastroenterology (1975) 69 1045-1047.
67. Whittle B.J.R. Temporal relationship between cyclo-oxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology (1981) 80 94-98.
68. Bjarnason I., Zanelli G., Smith T. et al. Non-steroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology (1987) 93 480-489.
69. Sigthorsson G., Tibble J., Hayllar J. et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut (1998) 43 506-511.
70. Sigthorsson G., Jacob M., Wrigglesworth J., Somasundaram S., Tavares I., Foster R., Roseth A., Rafi S., Mahmud T., Simpson R., Bjarnason I. Comparison of indomethacin and nimesulide, a selective cyclo-oxygenase-2 inhibitor, on key pathophysiologic steps in enteropathy. Scand. J. Gastroenterol. (1998) 33 728-735.
71. Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology (1997) 112 109-117.
72. Whittle B.J.R., Laszlo F., Evans S.M., Moncada S. Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br. J. Pharmacol. (1995) 116 2286-2290.
73. Evans S.M., Whittle B.J.R. Interactive roles of superoxide and inducible nitric oxide synthase in rat intestinal injury provoked by non-steriodal anti-inflammatory drugs. Eur. J. Phamacol. (2001) 429 287-296.
74. Bertrand V., Guimbaud R., Sogni P. et al. Role of tumour necrosis factor-alpha and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity. Eur. J. Pharmacol. (1998) 356 245-253.
75. Konaka A., Nishijima M., Tanaka A., Kunikata T., Kato S., Takeuchi K. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats. J. Physiol. Pharmacol. (1999) 50 25-38.
76. Sigthorsson G., Crane R., Simon T., Hoover M., Quan H., Bolognese J., Bjarnason I. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut (2000) 47 527-532.
77. Russell R.I. Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins. Rheumatol. Int. (1990) 10 17-21.
78. Shah A.A., Murray F.E., Fitzgerald D.J. The in vivo assessment of nimesulide cyclo-oxygenase-2 selectivity. Rheumatology (1999) 38 19-23.
79. Wober W. Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder and a meta-analysis of controlled studies with nimesulide. Rheumatology (1999) 38 33-38.
80. Lucker P.W., Pawlowski C., Friedrich I., Faiella F., Magni E. Double-blind randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac in patients suffering from osteoarthritis of the knee. Eur. J. Rheumatol. Inflamm. (1994) 14 29-38.
81. Schnitzer T.J., Ballard I.M., Constantine G., McDonald P. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Clin. ther. (1995) 17 602-612.
82. Hawkey C., Kahan A., Steinbruck K., Alegre C. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br. J. Rheumatol. (1998) 37 937-945.
83. Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclo-oxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. (1998) 37 946-951.
84. Emery P., Zeidler H., Kvien T.K., Guslandi M. et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (1999) 354 106-111.
85. Simon L.S., Weaver A.L., Graham D.Y. et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 242 1921-1928.
86. Langman M.J., Jensen D.M., Watson D.J. et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA (1999) 282 1929-1933.
87. Laine L., Harper S., Simon T. et al. A randomized trial comparing the effect of rofecoxib, a cyclo-oxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology (1999) 117 776-783.
88. Silverstein F.E., Faich G., Goldstein J.L. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284 1247-1255.
89. Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343 1520-1528.
90. Juni P., Rutjes A.W., Dieppe P.A. Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drug? BMJ (2002) 321 1287-1288.
91. Deeks J.J., Smith L.A., Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ (2002) 325 619-623.
92. Mamdani M., Rochon P.A., Juurlink D.N. et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ (2002) 325 624-627.
93. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclo-oxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA (1999) 96 272-277.
94. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286 954-959.
95. White W.B., Faich G., Whelton A. et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol. (2002) 89 425-430.
96. Reuter B.K., Asfaha S., Buret A., Sharkey K.A., Wallace J.L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclo-oxygenase-2. J. Clin. Invest. (1996) 98 2076-2085.
97. Lesch C.A., Kraus E.R., Sanchez B., Gilbertsen R., Guglietta A. Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis. Methods Find. Exp. Clin. Pharmacol. (1999) 21 99-104.
98. Yeomans N., Hawkey C., Lanas A., Naesdal J., Talley N., Thomson A. Prevalence of gastric and duodenal ulcers during treatment with 'low-dose' aspirin. Gastroenterology (2002) 122 A-87.
99. Eisen G., Goldstein J.L., Stenson W., Agrawal N., Kent J., Fort J.G. Lack of correlation between risk factors and clinical GI outcomes in NSAID-treated patients. Gastroenterology (2002) 122 A-346.
100. Fiorucci S., Santucci L., Mencarelli A., Del Soldato P., Morelli A. Gastrointestinal safety of a NO-releasing aspirin derivative, (NCX4016) in humans: a double blind placebo controlled endoscopic study. Gastroenterology (2002) 122 Ab-151.
101. Hawkey C.J., Jones J.I.W., Atherton C.T. et al. Gastrointestinal safety of AZD3582: A new chemical entity with a novel multi-path mechanism of action. Gastroenterology (2002) 122 A-54.
102. Laine L., Connors L.G., Reicin A., Yu Q., Bombardier C. Serious lower GI events with non-selective NSAID or coxib use: a double-blind GI outcomes trial of naproxen vs rofecoxib. Gastroenterology (2002) 122 Ab-146.
103. Goldstein J.L., Stenson W., Agrawal N. et al. Valdecoxib is associated with a significant lower incidence of ulcer complications and symptomatic ulcers in arthritis patients as compared to NSAID. Gastroenterology (2002) 122 A-465.
104. Hawkey C. and PUCCINI Group. Reduced cumulative incidence of gastroduodenal ulcers with two does of a new coxib. COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients. Gastroenterology (2002) 122 A-345.
105. Chandrasekharan N.V., Dai H. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetominiphen and other analgesic/antipyretic drugs: Cloning. structure, and expression. Proc. Natl. Acad. Sci. USA (2002) 99 13926-13931.